Scientific Industries Completes Strategic Refocus and Secures Proceeds of $10 million to Accelerate Growth of Two Data-Driven Business Platforms; Divests Genie® Division to OHAUS Corporation’s affiliate Troemner, LLC
Scientific Industries (OTCQB: SCND) has completed a strategic transformation by selling its Genie Division to Troemner, LLC for $9.6 million in cash, plus potential earnout of up to $1.5 million. The company is pivoting from its 70-year legacy in vortexing technologies to focus on two AI-driven platforms: pharmacy automation through VIVID and biomanufacturing with DOTS™.
The VIVID platform, developed by the Torbal division, has deployed nearly 2,000 units for automated pill counting and is developing the industry's first ML pill library for Q1 2026. The Scientific Bioprocessing division's DOTS™ platform aims to digitize bioproduction with real-time data capabilities.
The company secured $1.5 million in additional financing through stock and warrant sales in April 2025. Combined with previous funding of $27 million since 2020 and the Genie division sale proceeds, Scientific Industries is positioned to accelerate growth in its digital platforms.
Scientific Industries (OTCQB: SCND) ha completato una trasformazione strategica vendendo la sua divisione Genie a Troemner, LLC per 9,6 milioni di dollari in contanti, più un potenziale earnout fino a 1,5 milioni di dollari. L'azienda sta abbandonando i suoi 70 anni di esperienza nelle tecnologie di vortexing per concentrarsi su due piattaforme basate sull'intelligenza artificiale: l'automazione farmaceutica con VIVID e la bioproduzione con DOTS™.
La piattaforma VIVID, sviluppata dalla divisione Torbal, ha installato quasi 2.000 unità per il conteggio automatico delle pillole e sta sviluppando la prima libreria di pillole con machine learning del settore, prevista per il primo trimestre del 2026. La divisione Scientific Bioprocessing con la piattaforma DOTS™ punta a digitalizzare la bioproduzione con funzionalità di dati in tempo reale.
L'azienda ha ottenuto 1,5 milioni di dollari di finanziamenti aggiuntivi tramite la vendita di azioni e warrant nell'aprile 2025. Insieme ai precedenti finanziamenti per 27 milioni di dollari dal 2020 e ai proventi della vendita della divisione Genie, Scientific Industries è pronta ad accelerare la crescita delle sue piattaforme digitali.
Scientific Industries (OTCQB: SCND) ha completado una transformación estratégica al vender su división Genie a Troemner, LLC por 9,6 millones de dólares en efectivo, más un posible earnout de hasta 1,5 millones de dólares. La compañía está cambiando su enfoque tras 70 años en tecnologías de vortex para centrarse en dos plataformas impulsadas por IA: automatización farmacéutica a través de VIVID y bioproducción con DOTS™.
La plataforma VIVID, desarrollada por la división Torbal, ha desplegado casi 2.000 unidades para el conteo automatizado de pastillas y está desarrollando la primera biblioteca de pastillas con aprendizaje automático de la industria, prevista para el primer trimestre de 2026. La división Scientific Bioprocessing con la plataforma DOTS™ busca digitalizar la bioproducción con capacidades de datos en tiempo real.
La empresa aseguró 1,5 millones de dólares en financiamiento adicional mediante la venta de acciones y warrants en abril de 2025. Sumado a la financiación previa de 27 millones de dólares desde 2020 y los ingresos por la venta de la división Genie, Scientific Industries está posicionada para acelerar el crecimiento de sus plataformas digitales.
Scientific Industries (OTCQB: SCND)는 Genie 부서를 Troemner, LLC에 현금 960만 달러에 매각하고 최대 150만 달러의 추가 수익 가능성을 포함한 전략적 전환을 완료했습니다. 회사는 70년간의 보텍스 기술 전통에서 벗어나 AI 기반 두 플랫폼에 집중합니다: 약국 자동화 플랫폼 VIVID와 생명공학 제조 플랫폼 DOTS™입니다.
Torbal 부서가 개발한 VIVID 플랫폼은 자동 알약 계수를 위해 거의 2,000대가 배치되었으며, 2026년 1분기에 업계 최초의 기계 학습 기반 알약 라이브러리를 개발 중입니다. Scientific Bioprocessing 부서의 DOTS™ 플랫폼은 실시간 데이터 기능을 통해 생명공학 생산을 디지털화하는 것을 목표로 합니다.
회사는 2025년 4월 주식 및 워런트 판매를 통해 150만 달러의 추가 자금을 확보했습니다. 2020년 이후 2,700만 달러의 이전 자금 조달과 Genie 부서 매각 수익과 결합하여 Scientific Industries는 디지털 플랫폼 성장을 가속화할 준비가 되어 있습니다.
Scientific Industries (OTCQB : SCND) a achevé une transformation stratégique en vendant sa division Genie à Troemner, LLC pour 9,6 millions de dollars en espèces, plus un earnout potentiel pouvant atteindre 1,5 million de dollars. L'entreprise se détourne de ses 70 ans d'expertise dans les technologies de vortex pour se concentrer sur deux plateformes pilotées par l'IA : l'automatisation pharmaceutique avec VIVID et la bioproduction avec DOTS™.
La plateforme VIVID, développée par la division Torbal, a déployé près de 2 000 unités pour le comptage automatisé de pilules et développe la première bibliothèque de pilules basée sur le machine learning de l'industrie, prévue pour le premier trimestre 2026. La division Scientific Bioprocessing avec la plateforme DOTS™ vise à digitaliser la bioproduction grâce à des capacités de données en temps réel.
L'entreprise a obtenu un financement supplémentaire de 1,5 million de dollars en avril 2025 via la vente d'actions et de bons de souscription. Associé aux financements antérieurs de 27 millions de dollars depuis 2020 et aux recettes de la vente de la division Genie, Scientific Industries est bien positionnée pour accélérer la croissance de ses plateformes numériques.
Scientific Industries (OTCQB: SCND) hat eine strategische Transformation abgeschlossen, indem es seine Genie-Division für 9,6 Millionen US-Dollar in bar an Troemner, LLC verkauft hat, zuzüglich eines möglichen Earnouts von bis zu 1,5 Millionen US-Dollar. Das Unternehmen wandelt sich von seiner 70-jährigen Tradition in Vortex-Technologien hin zu zwei KI-gesteuerten Plattformen: Apothekenautomatisierung durch VIVID und Bioproduktion mit DOTS™.
Die VIVID-Plattform, entwickelt von der Torbal-Division, hat fast 2.000 Einheiten für automatisiertes Pillenzählen installiert und entwickelt die erste ML-basierte Pillenbibliothek der Branche für das erste Quartal 2026. Die Scientific Bioprocessing-Division mit der DOTS™-Plattform zielt darauf ab, die Bioproduktion mit Echtzeitdaten zu digitalisieren.
Das Unternehmen sicherte sich im April 2025 zusätzliche 1,5 Millionen US-Dollar Finanzierung durch Aktien- und Optionsverkäufe. Zusammen mit den bisherigen Finanzierungen von 27 Millionen US-Dollar seit 2020 und den Erlösen aus dem Verkauf der Genie-Division ist Scientific Industries gut positioniert, um das Wachstum seiner digitalen Plattformen zu beschleunigen.
- Strategic sale of Genie Division for $9.6 million plus potential $1.5 million earnout
- Strong market penetration with 2,000 VIVID units deployed
- Secured $1.5 million additional financing from existing investors
- Well-capitalized with over $27 million raised since 2020
- Development of industry's first machine learning pill library for Q1 2026
- Exit from established 70-year legacy business in vortexing technologies
- Transition period requiring continued support to buyer for up to one year
Realign priorities - AI-powered platforms to accelerate innovation and market leadership
Driving transformation in pharmacy automation with VIVID’s advanced solutions
Advancing AI-powered biomanufacturing with SBI’s DOTS Platform
BOHEMIA, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Scientific Industries Inc. (OTCQB: SCND) (the “Company”) announced that it has sold its Genie Division to Troemner, LLC, a manufacturing sister company of OHAUS Corporation, (the “Buyer”) for
Strategic Refocus on High-Growth, AI-Driven Platforms
“For more than 70 years, Scientific Industries was known as the world leader in vortexing technologies and as the pioneer and inventor of the vortex mixer,” said Helena Santos, CEO of Scientific Industries. “Today, we are transforming into a deep-tech, AI-enabling company focused on two of the pharmacy and pharmaceutical industries’ largest opportunities: pharmacy automation and biomanufacturing. With SaaS-enabled, data-driven IP models and integrated hardware/software platforms, we are building long-term value for our shareholders and measurable impact for our customers.”
Transforming Pharmacy Automation with VIVID
Scientific Industries’ Torbal division has rapidly evolved from analog pharmacy scales to become a leader in cloud-based pharmacy automation. The company launched its first VIVID automated pill counter in 2020 in response to the nationwide shortage of pharmacists, often referred to as “Pharmageddon.” Since then, the platform has expanded to three devices, including the VIVID Workstation — a premier cloud-connected automated pill counting solution.
To date, nearly 2,000 VIVID units have been deployed, supporting the monthly dispensing of millions of prescriptions. Scientific Industries is now developing the pharmacy industry’s first machine learning (“ML”) pill library, expected to launch in Q1 2026. This will allow the platform to continuously improve in accuracy and efficiency, create a robust data library and unlock new opportunities across the pharmacy value chain — from manufacturers and dispensers to law enforcement.
“Our vision is to become the ‘digital leader of retail pharmacy’ by providing critical infrastructure and intelligence to an underserved market of 24,000+ independent pharmacies in North America,” added Ms. Santos.
Unlocking AI-Enabled Biomanufacturing with Scientific Bioprocessing
The Company’s second core platform, Scientific Bioprocessing, is pioneering the digitization of analog bioproduction with its real-time DOTS™ platform. By converting complex biological signals into machine-readable data, the platform lays the foundation for predictive, automated, and scalable biomanufacturing.
“AI has made strides across life sciences, but biomanufacturing lags behind — not due to lack of algorithms, but due to lack of usable data,” explained John Moore, Chairman of Scientific Industries. “Our DOTS platform fills this gap, enabling automated, parallelized, and cost-effective data generation for smarter biologics, cell therapies, and bio-based production.”
Capital Reallocation to Accelerate Platform Growth
On April 18, 2025, Scientific Industries secured
With over
“By exiting our legacy analog business and focusing on digital infrastructure, we’re positioning Scientific Industries as a foundational technology provider for the next generation of intelligent life science operations,” said Mr. Moore. “The future belongs to those who can measure, learn, and act in real-time.”
BroadOak Capital Partners acted as financial advisor to the company on the divestiture.
About Scientific Industries
Scientific Industries (OTCQB: SCND), is a life science tool provider. It manufactures laboratory equipment, pill counters, and bioprocessing systems under the product name DOTS. Scientific Industries’ products are generally used for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com.
About OHAUS Corporation
Headquartered in Parsippany, NJ, OHAUS Corporation manufactures an extensive line of high-precision electronic and mechanical balances, laboratory equipment, centrifuges and analytical instruments. OHAUS is a global leader in laboratory, industrial, and education markets as well as a host of specialty markets, including food preparation, pharmacy and jewelry. The Genie portfolio of products will join the OHAUS brand and portfolio of Laboratory Equipment, Centrifuges and Balances
Forward Looking Statements
“Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company’s Securities and Exchange Commission reports, including our annual report on Form 10-K.”
| Company Contact: | ||
| Helena R. Santos CEO and President Phone: 631-567-4700 hsantos@scientificindustries.com info@scientificindustries.com | or: Joe Dorame Lytham Partners, LLC Phone: (602)889-9700 SCND@lythampartners.com | |
FAQ
How much did Scientific Industries (SCND) sell its Genie Division for?
What are Scientific Industries' new focus areas after selling Genie Division?
How many VIVID units has Scientific Industries deployed?
When will Scientific Industries launch its machine learning pill library?
How much funding has Scientific Industries raised since 2020?
